NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
Clinical Trials
49 trialsNCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT02349867 2022-09-19
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer
Virginia Commonwealth University
Phase 1 Completed
NCT00981162 2022-09-13
Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride
Roswell Park Cancer Institute
Phase 1 Completed
NCT02358395 2022-04-12
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT00892658 2021-10-06
Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP)
University Health Network, Toronto
Phase 1 Completed
NCT02292173 2021-06-10
Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT02642913 2021-03-05
Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02988440 2020-12-19
Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients
Novartis
Phase 1 Completed
NCT00823290 2020-12-14
Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC)
University of Erlangen-Nürnberg Medical School
Phase 1 Terminated
NCT02069145 2020-08-11
Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Mereo BioPharma
Phase 1 Completed
NCT02989870 2020-06-05
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Withdrawn
NCT01497444 2020-02-06
Sorafenib Tosylate and Hypoxia-Activated Prodrug TH-302 in Treating Patients With Advanced Kidney Cancer or Liver Cancer That Cannot Be Removed By Surgery
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT02240433 2020-02-05
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
Eli Lilly and Company
Phase 1 Completed
NCT02288507 2019-11-08
Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer
University of Hawaii
Phase 1 Withdrawn
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT01498952 2019-02-19
MEDI-573-1028
MedImmune LLC
Phase 1 Completed
NCT01011010 2018-01-05
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT00703638 2017-11-29
Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT01383343 2017-04-19
Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02323906 2017-03-20
Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer
Celgene
Phase 1 Terminated
NCT01308723 2016-11-02
A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1 Completed
NCT01897038 2016-11-02
A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma
Hoffmann-La Roche
Phase 1 Completed
NCT01640665 2016-09-16
Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors
Yale University
Phase 1 Completed
NCT00846131 2016-09-15
Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma
Northwestern University
Phase 1 Completed
NCT01376453 2016-09-12
Pre-operative 5-Fluorouracil (5-FU) and Sorafenib With External Radiation in Locally Advanced Rectal Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01008566 2016-05-12
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT02423239 2016-04-06
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
e-Therapeutics PLC
Phase 1 Unknown
NCT00375310 2016-02-29
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer
Indiana University
Phase 1 Completed
NCT01348503 2015-08-31
Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma
Indiana University
Phase 1 Terminated
NCT00997022 2015-08-10
Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients
Columbia University
Phase 1 Completed
NCT01801163 2015-04-16
A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Indiana University
Phase 1 Withdrawn
NCT00844168 2015-03-27
Sorafenib Tosylate in Treating Patients With Liver Cancer Who Have Undergone a Liver Transplant
University of Washington
Phase 1 Completed
NCT00134069 2014-04-16
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00827177 2014-01-24
Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Phase 1 Completed
NCT00956436 2013-09-16
Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC)
Biogen
Phase 1 Completed
NCT01618253 2013-09-05
Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma
Medical College of Wisconsin
Phase 1 Withdrawn
NCT00663741 2013-06-11
Sorafenib Gastric Cancer Asian Phase I Study
Bayer
Phase 1 Completed
NCT00780169 2013-05-13
Phase I Trial of Sorafenib + FOLFIRI In Metastatic Colorectal Cancer
Ottawa Hospital Research Institute
Phase 1 Completed
NCT00828594 2013-04-11
Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 1 Terminated
NCT01042041 2013-02-26
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00712855 2012-10-30
HCC
GlaxoSmithKline
Phase 1 Completed
NCT00767468 2012-05-23
Sorafenib in Treating Patients With Locally Advanced or Metastatic Liver Cancer and Cirrhosis
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT00873002 2012-03-20
Panobinostat and Sorafenib in Treating Patients With Liver Cancer That is Metastatic and/or Cannot Be Removed by Surgery
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT01131689 2012-02-02
Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma
Samsung Medical Center
Phase 1 Completed
NCT01441388 2011-12-20
A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors.
Pfizer
Phase 1 Withdrawn
NCT00478374 2010-11-02
S-TACE
University of Bern
Phase 1 Completed